Extended Data Fig. 1: Effect of ICV delivered CAR-T cells for UPN145 and patient overall survival and quality-of-life evaluations.

a, MR images of UPN145 under Arm 3 before (PRE, left panels) and after (POST, right panels) three ICV infusions of CAR-T cells at DS1 show that while the subpial lesions (yellow arrows) resolved, the parenchymal tumor (yellow circle) progressed. b, Overall survival of all evaluable patients from date of surgery. Thin lines denote 95% CIs; dashed lines depict medians in months (Mo). Median survival times with 95% CIs in parentheses are indicated. c, d, Survival comparisons of rGBM patients by dose schedule utilized for the DLT period. Legend of (c) and x-axis of (d) indicate maximum infusion cycle dose x 10⁶. Box and whisker plots of (d) depict the median and interquartile range with whiskers extending to the minimum and maximum values. P-values were determined using the two-sided Log-rank test (c) or an ANOVA test (d) across the different dose levels (n = 6, 4, 5, 17, and 9, left to right). e, Survival comparison of all evaluable patients that were infused with either Tcm- or Tn/mem-derived cell products. Red dots indicate censored participants (that is, lost to follow-up but hadn’t passed away). P-values for survival comparisons were determined using the Log-rank test. f, EROTC QLQ-C30 summary score slopes (change in QOL scores per day) from pre-surgery to ~ day 38 (encompassing the three infusions and DLT period) for all evaluable participants (top) or evaluable participants with rGBM (bottom) are shown as box and whisker plots. The median and interquartile range with whiskers extending to the last point within 1.5 times the interquartile range are depicted for Arms 1-4 vs. Arm 5. The means are indicated as blue filled circles. Note the pre-cycle 1 score was used as baseline for four participants who did not have pre-surgery scores, and for 3 participants, 1 question for the timepoint was imputed with cycle 1 results. P-values were calculated using the two-sided t-test.